
## Arum Kim

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5372829/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	ABT-737, a BH3 Mimetic, Enhances the Therapeutic Effects of Ionizing Radiation in K-ras Mutant Non-Small Cell Lung Cancer Preclinical Model. Yonsei Medical Journal, 2022, 63, 16.	2.2	9
2	Medical marijuana utilization in gynecologic cancer patients. Gynecologic Oncology Reports, 2021, 37, 100820.	0.6	6
3	Clinical implication and usefulness of de novo EGFR T790M mutation in lung adenocarcinoma with EGFR-tyrosine kinase inhibitor sensitizing mutation. Cancer Biology and Therapy, 2020, 21, 741-748.	3.4	6
4	An Isoform of the Oncogenic Splice Variant AIMP2-DX2 Detected by a Novel Monoclonal Antibody. Biomolecules, 2020, 10, 820.	4.0	1
5	Reactive oxygen species modulator 1 expression predicts lymph node metastasis and survival in early-stage non-small cell lung cancer. PLoS ONE, 2020, 15, e0239670.	2.5	1
6	Tumor clonal status predicts clinical outcomes of lung adenocarcinoma with EGFR-TKI sensitizing mutation. Journal of Cancer, 2019, 10, 5549-5556.	2.5	4
7	Presence of mEGFR ctDNA predicts a poor clinical outcome in lung adenocarcinoma. Thoracic Cancer, 2019, 10, 2267-2273.	1.9	9
8	Therapeutic effects of the novel Leucyl-tRNA synthetase inhibitor BC-LI-0186 in non-small cell lung cancer. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591984679.	3.2	16
9	Methionyl-tRNA Synthetase is a Useful Diagnostic Marker for Lymph Node Metastasis in Non-Small Cell Lung Cancer. Yonsei Medical Journal, 2019, 60, 1005.	2.2	10
10	Different mutational characteristics of the subsets of EGFR-tyrosine kinase inhibitor sensitizing mutation-positive lung adenocarcinoma. BMC Cancer, 2018, 18, 1221.	2.6	10
11	MYC expression correlates with PD-L1 expression in non-small cell lung cancer. Lung Cancer, 2017, 110, 63-67.	2.0	86
12	ABT-737 Synergizes with Cisplatin Bypassing Aberration of Apoptotic Pathway in Non-small Cell Lung Cancer. Neoplasia, 2017, 19, 354-363.	5.3	27
13	Keratinization of Lung Squamous Cell Carcinoma Is Associated with Poor Clinical Outcome. Tuberculosis and Respiratory Diseases, 2017, 80, 179.	1.8	25
14	Methionyl-tRNA synthetase overexpression is associated with poor clinical outcomes in non-small cell lung cancer. BMC Cancer, 2017, 17, 467.	2.6	32
15	Ratio of Autoantibodies of Tumor Suppressor AIMP2 and Its Oncogenic Variant Is Associated with Clinical Outcome in Lung Cancer. Journal of Cancer, 2017, 8, 1347-1354.	2.5	17
16	Genetic heterogeneity of actionable genes between primary and metastatic tumor in lung adenocarcinoma. BMC Cancer, 2016, 16, 27.	2.6	30
17	AZD6244 inhibits cisplatin-induced ERK1/2 activation and potentiates cisplatin-associated cytotoxicity in K-ras G12D preclinical models. Cancer Letters, 2015, 358, 85-91.	7.2	16
18	BCL2-like 11 intron 2 deletion polymorphism is not associated with non-small cell lung cancer risk and prognosis. Lung Cancer, 2015, 90, 106-110.	2.0	10

#	Article	IF	CITATIONS
19	KRAS oncogene substitutions in Korean NSCLC patients: Clinical implication and relationship with pAKT and RalGTPases expression. Lung Cancer, 2014, 85, 299-305.	2.0	12
20	Notch1 destabilizes the adherens junction complex through upregulation of the Snail family of E-cadherin repressors in non-small cell lung cancer. Oncology Reports, 2013, 30, 1423-1429.	2.6	17